GO:0015349 thyroid hormone transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015349 describes the molecular function that moves thyroid hormones, mainly thyroxine (T4) and triiodothyronine (T3), across biological membranes.
• The major transporters include monocarboxylate transporters such as MCT8 (SLC16A2) and MCT10 (SLC16A10), plus organic anion transporting polypeptides (OATPs) and L-type amino acid transporters.
• Defective thyroid hormone transport causes Allan-Herndon-Dudley syndrome, a severe X-linked neurodevelopmental disorder linked to MCT8 mutations.
• Transport activity can be measured with fluorescent probes, radiolabeled hormone uptake assays, and genetic models in cells and animals.
• Tissue-specific expression of transporters determines local thyroid hormone availability, influencing brain development, muscle metabolism, and liver function.
• CRISPR-based knockout, knock-in, and overexpression models are powerful tools to dissect the causal roles of individual transporters in health and disease.
Description
Thyroid hormones are essential for normal development, growth, and metabolic homeostasis. While they circulate in the bloodstream, their action depends on efficient transfer across cell membranes, a process mediated by specific transporter proteins. The Gene Ontology term GO:0015349, thyroid hormone transmembrane transporter activity, captures this critical molecular function. Understanding this activity is fundamental for researchers studying endocrine signaling, neurodevelopment, and metabolic disorders. The transporters involved belong to several solute carrier (SLC) families, including monocarboxylate transporters (MCT8, MCT10) and organic anion transporting polypeptides (OATPs). Their dysfunction has been directly linked to human disease, most notably Allan-Herndon-Dudley syndrome caused by MCT8 mutations. Moreover, recent studies have identified additional transporters for the thyroid hormone analog TRIAC, expanding the repertoire of proteins that mediate thyroid hormone transmembrane transport. This article provides a research-grade overview of GO:0015349, covering its definition, molecular mechanism, key genes, disease relevance, and state-of-the-art methods for investigation, including CRISPR-based models.
thyroid hormone transmembrane transporter activity At A Glance
| GO ID | GO:0015349 |
|---|---|
| GO term | thyroid hormone transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Transfer of thyroid hormones (T4, T3) across membranes |
| Major transporters | MCT8 (SLC16A2), MCT10 (SLC16A10), OATPs, LATs |
| Associated disease | Allan-Herndon-Dudley syndrome (MCT8 mutations) |
| Research methods | Uptake assays, fluorescent probes, CRISPR models |
What Is GO:0015349?
GO:0015349, thyroid hormone transmembrane transporter activity, is a molecular function defined as enabling the transfer of thyroid hormones from one side of a membrane to the other. Thyroid hormones are compounds secreted by the thyroid gland, primarily thyroxine (T4) and triiodothyronine (T3). This activity is essential for delivering these hormones to target tissues and cells, where they regulate gene expression and metabolism.
Why Is thyroid hormone transmembrane transporter activity Important in Cell Biology?
Thyroid hormone transmembrane transporter activity is crucial because it determines the availability of active thyroid hormones within cells. Without proper transport, hormones cannot reach their nuclear receptors, leading to impaired gene regulation and severe physiological consequences. This function is particularly important in the brain, where MCT8-mediated transport is required for neuronal development and function. Defects in this activity cause Allan-Herndon-Dudley syndrome, characterized by severe intellectual disability and motor dysfunction. Additionally, altered transporter expression has been implicated in metabolic disorders and cancer, making it a potential therapeutic target.
• Essential for brain development: MCT8 transports T4 and T3 into neurons, and its deficiency causes severe neurodevelopmental delay.
• Regulates systemic metabolism: Thyroid hormones control energy expenditure, and transport activity modulates their access to liver, muscle, and adipose tissues.
• Linked to Allan-Herndon-Dudley syndrome: mutations in SLC16A2 (MCT8) are the primary cause of this X-linked disorder.
• Influences muscle physiology: MCT10 (SLC16A10) is regulated by Six1 and affects skeletal muscle thyroid hormone response.
• Potential role in cancer: altered expression of thyroid hormone transporters has been observed in various tumors, affecting proliferation and differentiation.
• Target for drug development: modulating transporter activity could treat thyroid hormone resistance or enhance hormone delivery.
• Required for TRIAC transport: recently identified transporters for the thyroid hormone analog TRIAC expand therapeutic options.
• Methodological advances: fluorescent probes enable real-time monitoring of transport activity in live cells.
• CRISPR models facilitate functional studies: knockout and knock-in of transporter genes clarify their specific roles.
• Contributes to endocrine signaling: transport is a prerequisite for thyroid hormone action in target tissues.
Molecular Mechanism of thyroid hormone transmembrane transporter activity
Substrate recognition and binding
In simple terms: The transporter protein recognizes and binds thyroid hormones like T4 and T3.
Thyroid hormone transporters, such as MCT8 and MCT10, belong to the monocarboxylate transporter family and facilitate the passage of iodothyronines across the plasma membrane. These proteins contain specific binding pockets that accommodate the aromatic rings and iodine atoms of thyroid hormones. Substrate specificity varies: MCT8 transports T4, T3, and reverse T3 with high affinity, while MCT10 prefers T3 and aromatic amino acids. OATPs are also involved in thyroid hormone uptake in the liver and brain. The binding affinity and transport kinetics have been characterized using radiolabeled hormone uptake assays and, more recently, fluorescent probes.
Translocation across the membrane
In simple terms: The transporter undergoes conformational changes to move the hormone from one side of the membrane to the other.
After binding, the transporter undergoes conformational changes that allow the hormone to cross the lipid bilayer. MCT8 is thought to function as a facilitative transporter, moving thyroid hormones down their concentration gradient without direct ATP consumption. The transport cycle involves alternating access of the substrate-binding site to either side of the membrane. For OATPs, transport is often coupled to the movement of ions such as sodium or chloride, although the exact stoichiometry for thyroid hormones remains under investigation. Recent studies have identified additional transporters for TRIAC, suggesting diversity in translocation mechanisms.
Regulation of transporter expression and activity
In simple terms: Cells control how much hormone gets in by adjusting the number and activity of transporters.
The expression of thyroid hormone transporters is regulated at transcriptional and post-transcriptional levels. For example, the transcription factor Six1 promotes skeletal muscle thyroid hormone response by upregulating MCT10 (SLC16A10). Hormonal feedback, such as changes in thyroid hormone levels, can also affect transporter expression. In the brain, MCT8 expression is developmentally regulated, with high levels during critical periods of neurogenesis. Post-translational modifications and interactions with accessory proteins may further modulate transport activity. Understanding these regulatory mechanisms is essential for interpreting physiological and pathological states.
Cellular uptake and downstream effects
In simple terms: Once inside the cell, thyroid hormones can bind to receptors and change gene expression.
After entering the cell, T4 is often converted to the more active T3 by deiodinases. T3 then binds to nuclear thyroid hormone receptors (TRs), which regulate target gene transcription. Thus, transporter activity directly influences the cellular response to thyroid hormones. In the brain, MCT8-mediated transport is critical for providing T3 to neurons and glia, and its absence leads to hypomyelination and neuronal dysfunction. In muscle, MCT10-mediated transport supports metabolic gene expression. Therefore, the molecular function of thyroid hormone transmembrane transport is a key checkpoint in endocrine signaling.
Key Genes Involved in GO:0015349 thyroid hormone transmembrane transporter activity
The following genes encode proteins that exhibit thyroid hormone transmembrane transporter activity or are directly involved in this function, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC16A2 (MCT8) | High-affinity transporter for T4, T3, and reverse T3 | Mutations cause Allan-Herndon-Dudley syndrome; key for brain thyroid hormone uptake |
| SLC16A10 (MCT10) | Transports T3 and aromatic amino acids | Regulated by Six1 in skeletal muscle; affects muscle metabolism |
| SLCO1C1 (OATP1C1) | Transports T4 and T3 in brain and liver | May compensate for MCT8 deficiency in some tissues |
| SLCO1A2 (OATP1A2) | Transports thyroid hormones and other organic anions | Expressed in brain, liver, and kidney; potential drug target |
| SLCO1B1 (OATP1B1) | Mediates hepatic uptake of T4 and T3 | Influences thyroid hormone clearance and drug interactions |
| SLCO1B3 (OATP1B3) | Transports thyroid hormones in liver | May affect systemic hormone levels |
| SLC7A5 (LAT1) | Transports T3 and T4 in exchange for amino acids | Highly expressed in brain and tumors; contributes to hormone uptake |
| SLC7A8 (LAT2) | Transports thyroid hormones in kidney and brain | Potential role in local hormone delivery |
| SLC16A1 (MCT1) | Low-affinity transporter for T3 and T4 | Broadly expressed; may facilitate hormone uptake in muscle |
| SLC16A3 (MCT4) | Transports T3 and T4 with low affinity | Upregulated in hypoxia; may affect hormone availability in tumors |
| SLC16A7 (MCT2) | Transports T3 and T4 in neurons | May contribute to brain thyroid hormone uptake |
| SLC21A2 (OATP2) | Transports thyroid hormones in liver | Historical name for OATP1B1; involved in hormone clearance |
| SLC22A1 (OCT1) | Transports T4 and T3 in liver and kidney | May influence hormone distribution |
| SLC22A2 (OCT2) | Transports thyroid hormones in kidney | Potential role in renal hormone handling |
| SLC22A3 (OCT3) | Transports T4 and T3 in brain and heart | May modulate local hormone levels |
| SLC15A1 (PEPT1) | Transports T3 and T4 in intestine | May affect oral hormone absorption |
| SLC15A2 (PEPT2) | Transports thyroid hormones in kidney and brain | Potential role in hormone reabsorption |
| SLC10A1 (NTCP) | Transports T4 and T3 in liver | Involved in hepatic hormone uptake |
How Is thyroid hormone transmembrane transporter activity Regulated?
Thyroid hormone transmembrane transporter activity is regulated at multiple levels. Transcriptional regulation includes the action of tissue-specific transcription factors such as Six1, which promotes MCT10 expression in skeletal muscle. Hormonal feedback can also modulate transporter expression; for example, thyroid hormone levels themselves can influence MCT8 and OATP expression in the brain. Post-translational mechanisms, such as phosphorylation and ubiquitination, may affect transporter trafficking and stability. Additionally, interactions with accessory proteins like CD147 (basigin) are required for proper folding and plasma membrane localization of some MCTs. In pathological states, inflammatory cytokines and hypoxia can alter transporter expression, impacting hormone delivery to tissues.
thyroid hormone transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC16A2 (MCT8) | Allan-Herndon-Dudley syndrome | Knockout mouse, patient-derived iPSCs, knock-in of patient mutations |
| SLC16A10 (MCT10) | Muscle metabolism, thyroid hormone response | Muscle-specific knockout, overexpression in C2C12 cells |
| SLC7A5 (LAT1) | Cancer proliferation, brain development | Tumor xenografts with knockout, brain-specific knockout |
| SLCO1C1 (OATP1C1) | Brain thyroid hormone transport, hypothyroidism | Knockout mouse, astrocyte-specific overexpression |
| SLC16A2 (MCT8) | Neurodevelopmental disorders | CRISPR knock-in of patient mutations in zebrafish |
Allan-Herndon-Dudley syndrome (MCT8 deficiency)
Mutations in SLC16A2, which encodes MCT8, cause Allan-Herndon-Dudley syndrome (AHDS), an X-linked disorder characterized by severe intellectual disability, dysarthria, spastic paraplegia, and abnormal thyroid hormone levels. The loss of MCT8 function impairs T3 uptake into neurons, leading to hypomyelination and neuronal dysfunction. Current treatments focus on symptomatic management and thyroid hormone analogs, but effective therapies are lacking.
Metabolic disorders and muscle function
Thyroid hormone transporters influence systemic metabolism. MCT10 (SLC16A10) is regulated by Six1 in skeletal muscle, and its expression affects muscle thyroid hormone response and metabolic gene expression. Altered transporter activity has been linked to insulin resistance and obesity, although the precise mechanisms remain under investigation. Targeting these transporters could offer new strategies for metabolic diseases.
Cancer
Thyroid hormone transporters are differentially expressed in various cancers. For example, LAT1 (SLC7A5) is overexpressed in many tumors and transports thyroid hormones, potentially supporting cancer cell proliferation. MCT8 expression is altered in some thyroid cancers, and its role in tumor progression is being explored. Understanding how transporter activity contributes to cancer biology may reveal novel therapeutic targets.
Neurodevelopmental and neurodegenerative conditions
Proper thyroid hormone transport is essential for brain development. Beyond AHDS, polymorphisms in transporter genes have been associated with cognitive deficits and neurodegenerative diseases. In Alzheimer's disease, altered thyroid hormone levels and transport have been observed, though causality is not established. Further research using CRISPR models may clarify the contribution of specific transporters to neurodegeneration.
From thyroid hormone transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MCT8 mediate T3 uptake in neurons? | MCT8 knockout neurons differentiated from iPSCs |
| What is the effect of MCT10 overexpression on muscle metabolism? | AAV-mediated overexpression in mouse skeletal muscle |
| Can a point mutation in SLC16A2 recapitulate AHDS? | Knock-in mouse carrying patient mutation |
| Which transporters compensate for MCT8 deficiency? | Double knockout of MCT8 and OATP1C1 in mice |
| How does TRIAC enter cells? | CRISPR knockout of candidate transporters in HEK293 cells |
| Does LAT1 contribute to thyroid hormone uptake in cancer? | LAT1 knockout in cancer cell lines followed by uptake assays |
How to Study the thyroid hormone transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorescent probe uptake | Real-time transport activity | High-throughput screening of transporter function |
| Radiolabeled hormone uptake | Transport kinetics and specificity | Characterization of known and novel transporters |
| CRISPR knockout | Loss-of-function effects | Determining causal role of a transporter in hormone uptake |
| CRISPR knock-in | Disease mutation effects | Modeling Allan-Herndon-Dudley syndrome |
| RNA-seq | Transporter gene expression | Tissue-specific expression profiling |
| Proteomics | Protein abundance and interactions | Identifying accessory proteins and modifications |
| Immunofluorescence | Subcellular localization | Determining membrane vs intracellular localization |
| Patch-clamp or electrophysiology | Ion currents coupled to transport | Studying electrogenic transporters like OATPs |
Fluorescent probe-based transport assays
Recent advances include highly selective fluorescent probes that monitor thyroid hormone transporter activity in live mammalian cells. These probes allow real-time, high-throughput screening of transporter function and can be used to study kinetics and inhibition. They are particularly useful for identifying novel transporters and for drug discovery.
Radiolabeled hormone uptake assays
Classic methods use radiolabeled T4 or T3 to measure uptake in cells expressing candidate transporters. These assays provide quantitative data on transport rates and substrate specificity. They are often combined with kinetic analyses to determine Km and Vmax values.
CRISPR-Cas9 genome editing
CRISPR-Cas9 enables the generation of knockout, knock-in, and point-mutation models to study thyroid hormone transporters. Knockout cell lines and mice help determine the physiological roles of specific transporters. Knock-in models can replicate human disease mutations, such as those in SLC16A2, to study pathogenesis and test therapies.
Transcriptomics and proteomics
RNA-seq and proteomics can profile the expression of thyroid hormone transporters across tissues and conditions. These approaches identify regulatory networks and potential compensatory mechanisms. Integrating with clinical data can reveal biomarkers and therapeutic targets.
How CRISPR Can Be Used to Study GO:0015349 thyroid hormone transmembrane transporter activity
Knockout
CRISPR knockout of thyroid hormone transporter genes, such as SLC16A2 or SLC16A10, allows researchers to study loss-of-function phenotypes in cell lines and animal models. For example, MCT8 knockout mice exhibit altered brain thyroid hormone levels and behavioral deficits, mimicking aspects of Allan-Herndon-Dudley syndrome. Knockout studies are essential for establishing causality between transporter activity and physiological outcomes.
Point Mutation
Introducing specific point mutations found in patients into the endogenous gene locus using CRISPR base editing or homology-directed repair can replicate disease-causing alleles. For SLC16A2, numerous missense mutations have been identified in AHDS patients; modeling these in cells or mice helps understand genotype-phenotype correlations and test targeted therapies.
Knock-in
Knock-in of reporter tags (e.g., GFP) or epitope tags into transporter genes enables visualization and purification of the transporter protein in its native context. This is valuable for studying trafficking, localization, and interaction partners. Additionally, knock-in of human transporter genes into mouse models can humanize the system for drug testing.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of thyroid hormone transporters can enhance hormone uptake and amplify downstream signaling. Overexpression models are useful for studying the effects of increased transport on cell proliferation, metabolism, and differentiation. They can also be used to screen for compounds that modulate transporter activity.
How EDITGENE Supports thyroid hormone transmembrane transporter activity Research
Researchers studying thyroid hormone transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in hormone uptake, how mutations affect transport function, and whether modulating transporter levels can alter disease phenotypes. EDITGENE provides comprehensive CRISPR-based services to address these questions with precision and efficiency.
Contact EDITGENE today to design your custom CRISPR model for thyroid hormone transmembrane transporter activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SLCO1B1 Knockout HEK293 Cell Line | EDJ-KQ2079 | Human | 10599 | Details Get a Quote |
| SLC7A8 Knockout HEK293 Cell Line | EDC08226 | Human | 23428 | Details Get a Quote |
| SLC16A2 Knockout HEK293 Cell Line | EDJ-KQ5791 | Human | 6567 | Details Get a Quote |
| SLC17A4 Knockout HEK293 Cell Line | EDJ-KQ6878 | Human | 10050 | Details Get a Quote |
| SLC16A10 Knockout HEK293 Cell Line | EDJ-KQ7604 | Human | 117247 | Details Get a Quote |
| SLCO4A1 Knockout HEK293 Cell Line | EDJ-KQ8847 | Human | 28231 | Details Get a Quote |
| SLCO1C1 Knockout HEK293 Cell Line | EDJ-KQ11370 | Human | 53919 | Details Get a Quote |
| SLC7A5 Knockout HEK293 Cell Line | EDJ-KQ17900 | Human | 8140 | Details Get a Quote |
| SLC7A5 Knockout HeLa Cell Line | EDC08354 | Human | 8140 | Details Get a Quote |
| SLCO1B1 Knockout A-549 Cell Line | EDJ-KQ22162 | Human | 10599 | Details Get a Quote |
| SLCO1B1 Knockout HeLa Cell Line | EDJ-KQ22163 | Human | 10599 | Details Get a Quote |
| SLC16A2 Knockout A-549 Cell Line | EDJ-KQ29207 | Human | 6567 | Details Get a Quote |
| SLC16A10 Knockout A-549 Cell Line | EDJ-KQ32943 | Human | 117247 | Details Get a Quote |
| SLCO4A1 Knockout A-549 Cell Line | EDJ-KQ35158 | Human | 28231 | Details Get a Quote |
| SLCO4A1 Knockout HCT 116 Cell Line | EDJ-KQ35159 | Human | 28231 | Details Get a Quote |
Displaying Records 1 To 15 Of 32 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About thyroid hormone transmembrane transporter activity
What is thyroid hormone transmembrane transporter activity?
It is a molecular function (GO:0015349) that enables the transfer of thyroid hormones, primarily T4 and T3, across cell membranes.
What genes are involved in thyroid hormone transmembrane transport?
Key genes include SLC16A2 (MCT8), SLC16A10 (MCT10), SLCO1C1 (OATP1C1), and SLC7A5 (LAT1), among others.
What diseases are associated with defects in thyroid hormone transport?
Mutations in SLC16A2 cause Allan-Herndon-Dudley syndrome, a severe neurodevelopmental disorder. Altered transport is also linked to metabolic disorders and cancer.
How can I measure thyroid hormone transporter activity?
Fluorescent probes, radiolabeled hormone uptake assays, and electrophysiology are commonly used.
What is the role of MCT8 in the brain?
MCT8 transports T4 and T3 into neurons and glial cells, which is essential for brain development and function.
Can CRISPR be used to study thyroid hormone transporters?
Yes, CRISPR knockout, knock-in, and point mutation models are powerful tools to dissect transporter function and model diseases.
What is Allan-Herndon-Dudley syndrome?
It is an X-linked disorder caused by MCT8 mutations, characterized by intellectual disability, spasticity, and abnormal thyroid hormone levels.
Are there treatments for MCT8 deficiency?
Current treatments are symptomatic; thyroid hormone analogs like TRIAC are being investigated, and new transporters for TRIAC have been identified.
How is the expression of thyroid hormone transporters regulated?
Transcriptional factors like Six1 regulate MCT10 in muscle, and hormonal feedback can affect transporter levels in the brain.
What services does EDITGENE offer for studying thyroid hormone transporters?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression models, library screening, and bioinformatics analysis.
Conclusion
Thyroid hormone transmembrane transporter activity (GO:0015349) is a fundamental molecular function that governs the cellular entry of T4 and T3, thereby controlling thyroid hormone action. Dysregulation of this activity leads to severe diseases, including Allan-Herndon-Dudley syndrome, and contributes to metabolic and neoplastic disorders. Advances in fluorescent probes and CRISPR-based models are accelerating our understanding of transporter biology and opening new avenues for therapeutic intervention. EDITGENE stands ready to support researchers with tailored CRISPR solutions to explore this critical function.
References
- 1. Byrnes K et al.. 2022. Therapeutic regulation of autophagy in hepatic metabolism.. Acta Pharm Sin B 12(1):33-49 PMID: 35127371
- 2. Halestrap AP. 2013. The SLC16 gene family - structure, role and regulation in health and disease.. Mol Aspects Med 34(2-3):337-49 PMID: 23506875
- 3. Giri D et al.. 2024. A Highly Selective Fluorescent Probe for Monitoring the Thyroid Hormone Transporter Activity in Mammalian Cells.. Chemistry 30(54):e202401719 PMID: 38995511
- 5. Braun D et al.. 2010. Thyroid hormone transporters in the brain.. Rev Neurosci 21(3):173-86 PMID: 20879691
- 6. Groeneweg S et al.. 2017. Disorder of thyroid hormone transport into the tissues.. Best Pract Res Clin Endocrinol Metab 31(2):241-253 PMID: 28648511
- 7. Becker PC et al.. 2024. Identification of Human TRIAC Transmembrane Transporters.. Thyroid 34(7):920-930 PMID: 38801167
- 8. Girgis J et al.. 2021. Six1 promotes skeletal muscle thyroid hormone response through regulation of the MCT10 transporter.. Skelet Muscle 11(1):26 PMID: 34809717
